Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPreferred Stock LiabilitiesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Rhythm Pharmaceuticals (RYTM) Preferred Stock Liabilities (2016 - 2025)

Rhythm Pharmaceuticals (RYTM) has disclosed Preferred Stock Liabilities for 4 consecutive years, with $131.0 million as the latest value for Q4 2025.

  • On a quarterly basis, Preferred Stock Liabilities fell 8.31% to $131.0 million in Q4 2025 year-over-year; TTM through Dec 2025 was $131.0 million, a 8.31% decrease, with the full-year FY2025 number at $131.0 million, down 8.31% from a year prior.
  • Preferred Stock Liabilities was $131.0 million for Q4 2025 at Rhythm Pharmaceuticals, down from $146.9 million in the prior quarter.
  • In the past five years, Preferred Stock Liabilities ranged from a high of $146.9 million in Q3 2025 to a low of $131.0 million in Q4 2025.